MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition

By afschroeder • April 22, 2026

Schlaak M, Cimminiello C, Pigozzo J, Lee J, Grabbe S, Rutkowski P, Mackiewicz J, Tsai KK, Ascierto PA, Mandalà M, Carnevale-Schianca F, Haferkamp S, Atkinson V, Hassel JC, Sandhu S, Sharfman W, Dean E, Noor U, Iyer S, Rabbie R, Ribas A. MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition. Clin Cancer Res. 2026 Apr 21. doi: 10.1158/1078-0432.CCR-25-3951. Epub ahead of print. PMID: 42012456.

Tags: Hematology/Oncology, Publications

Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

Zhang R, Qi J, McKasson M, Choi J, Gutierrez V, Brennan C, Hong S, Chour W, Ng RH, Xie J, Yuan D, Webster A, Sidhu[...]

Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy

Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase[...]

Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care Coordination in Safety-Net Systems

Tupper HI, Doo FX, Lin Y, Flores EJ, Salinas DA, Cummings AL, Ryan GW, Revels SL. Mapping the Complexity of Cancer Screening and Multi-Disciplinary Care[...]